Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children With Functional Abdominal Pain (PMO)
Primary Purpose
Abdominal Pain
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Peppermint oil
Sponsored by
About this trial
This is an interventional treatment trial for Abdominal Pain
Eligibility Criteria
Inclusion Criteria:
- Children ages 7-12 years old
- They will be able to complete the protocol
- A child will be recruited if the medical evaluation reveals no organic reason for the abdominal pain
Exclusion Criteria:
- Children who have had past bowel surgery;
- A child with documented GI disorders (e.g., Crohn's disease);
- A child with a serious chronic medical condition (e.g., diabetes);
- A child with a weight and/or height < 2 SD for age;
- Children with chronic conditions with GI symptoms (e.g., cystic fibrosis);
- Children with autism spectrum disorder, significant developmental delay, psychosis, depression, or a history of bipolar disorder;
- Children who have been treated with antibiotics/probiotics within 2 mo. (because of effects on microbiome analysis).
- Children who speak only Spanish
Sites / Locations
- Texas Children's Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
180 mg
360 mg
540 mg
Arm Description
180 mg of peppermint oil
360 mg of peppermint oil
540 mg of peppermint oil
Outcomes
Primary Outcome Measures
Pharmacokinetics
Area under the curve
Secondary Outcome Measures
Contractility
Number and amplitude of gut contractions as measured by SmartPill
Gut Microbiome Composition
Microbiome is defined for this study as a statistically significant change from baseline after treatment with PMO, correcting for multiple testing (q value). Such changes may occur with respect to gut microbiome diversity and/or composition (e.g., phylum, family, genera). We anticipate there will be an increased bacterial diversity, as well as increases in the abundance of organisms associated with a healthy microbiome, in response to PMO administration.
Motility
Gut transit time as measured by SmartPill
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03295747
Brief Title
Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children With Functional Abdominal Pain
Acronym
PMO
Official Title
Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children With Functional Abdominal Pain
Study Type
Interventional
2. Study Status
Record Verification Date
April 2022
Overall Recruitment Status
Completed
Study Start Date
October 15, 2017 (Actual)
Primary Completion Date
March 28, 2019 (Actual)
Study Completion Date
March 28, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Robert Shulman, M.D.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Aim 1 - Determine the pharmacokinetics of PMO (menthol) of three different doses in children with functional abdominal pain (FAP) (n=30).
Aim 2 - Determine pharmacodynamic effect of three different doses of PMO on gut microbiome composition and contractile activity/gut transit rate.
Detailed Description
Children with functional abdominal pain (FAP) ages 7-12 years (n=30) will be recruited.
The study participants will be admitted to the Children's Nutrition Research Center. A medical history and a general physical examination performed by the investigator or the research nurse. The height, weight, and vital signs (pulse rate, respiratory rate, and seated blood pressure) will be obtained. After application of a topical anesthetic to the site chosen for study-related blood sampling, a cannula will be inserted e to obtain repeated blood samples.
At approximately 0900, subjects will receive one of three doses of PMO as a single oral dose. Immediately prior to administration of the PMO, a blood sample will be obtained to measure total menthol concentration and leukocytes for isolation of DNA for CYP2A6 and UGT2B7 genotyping.
After PMO administration, repeated blood samples will be obtained over 24 hours.
At 2 hours after PMO administration, participants will be given a standardized meal and will eat ad libitum thereafter.
After completion of the final (24 hours) blood samples, vital signs will be reassessed and the venous cannula removed. Parents will receive a follow-up call from the research coordinator to access/evaluate if any adverse effects from dose or blood sampling received at the overnight study visit.
Prior to and after administration of peppermint oil (PMO) for 1 week at the dose defined above, children will undergo measurement of gut microbiome composition and GI motility and transit time. At the time of the stool collection, the child will also keep a 3 day diet history.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Abdominal Pain
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Model Description
Participants randomized to one of three prospective arms as reflected by three treatment doses for the duration of the study.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
180 mg
Arm Type
Experimental
Arm Description
180 mg of peppermint oil
Arm Title
360 mg
Arm Type
Experimental
Arm Description
360 mg of peppermint oil
Arm Title
540 mg
Arm Type
Experimental
Arm Description
540 mg of peppermint oil
Intervention Type
Drug
Intervention Name(s)
Peppermint oil
Other Intervention Name(s)
Enteric coated peppermint oil capsules
Intervention Description
Three doses of peppermint oil will be investigated: 180, 360, 540 mg; i.e. three arms.
Primary Outcome Measure Information:
Title
Pharmacokinetics
Description
Area under the curve
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Contractility
Description
Number and amplitude of gut contractions as measured by SmartPill
Time Frame
Prior to and during peppermint oil treatment
Title
Gut Microbiome Composition
Description
Microbiome is defined for this study as a statistically significant change from baseline after treatment with PMO, correcting for multiple testing (q value). Such changes may occur with respect to gut microbiome diversity and/or composition (e.g., phylum, family, genera). We anticipate there will be an increased bacterial diversity, as well as increases in the abundance of organisms associated with a healthy microbiome, in response to PMO administration.
Time Frame
Prior to and during peppermint oil treatment
Title
Motility
Description
Gut transit time as measured by SmartPill
Time Frame
Prior to and during peppermint oil treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
7 Years
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Children ages 7-12 years old
They will be able to complete the protocol
A child will be recruited if the medical evaluation reveals no organic reason for the abdominal pain
Exclusion Criteria:
Children who have had past bowel surgery;
A child with documented GI disorders (e.g., Crohn's disease);
A child with a serious chronic medical condition (e.g., diabetes);
A child with a weight and/or height < 2 SD for age;
Children with chronic conditions with GI symptoms (e.g., cystic fibrosis);
Children with autism spectrum disorder, significant developmental delay, psychosis, depression, or a history of bipolar disorder;
Children who have been treated with antibiotics/probiotics within 2 mo. (because of effects on microbiome analysis).
Children who speak only Spanish
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shulman J. Shulman, MD
Organizational Affiliation
Baylor College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Texas Children's Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
34528282
Citation
Shulman RJ, Chumpitazi BP, Abdel-Rahman SM, Garg U, Musaad S, Kearns GL. Randomised trial: Peppermint oil (menthol) pharmacokinetics in children and effects on gut motility in children with functional abdominal pain. Br J Clin Pharmacol. 2022 Mar;88(3):1321-1333. doi: 10.1111/bcp.15076. Epub 2021 Oct 19. Erratum In: Br J Clin Pharmacol. 2022 Dec;88(12):5436.
Results Reference
result
PubMed Identifier
35048535
Citation
Thapa S, Luna RA, Chumpitazi BP, Oezguen N, Abdel-Rahman SM, Garg U, Musaad S, Versalovic J, Kearns GL, Shulman RJ. Peppermint oil effects on the gut microbiome in children with functional abdominal pain. Clin Transl Sci. 2022 Apr;15(4):1036-1049. doi: 10.1111/cts.13224. Epub 2022 Jan 20.
Results Reference
result
Learn more about this trial
Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children With Functional Abdominal Pain
We'll reach out to this number within 24 hrs